Litigation Details for GlaxoSmithKline LLC v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)
✉ Email this page to a colleague
GlaxoSmithKline LLC v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)
| Docket | ⤷ Try a Trial | Date Filed | 2014-07-03 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:145 Patent Infringement | Assigned To | Leonard Philip Stark |
| Jury Demand | Plaintiff | Referred To | Christopher J. Burke |
| Parties | GLAXOSMITHKLINE LLC; SMITHKLINE BEECHAM (CORK) LIMITED; TEVA PHARMACEUTICALS USA INC. | ||
| Patents | RE40; RE4448; RE4812 | ||
| Attorneys | Alexandra Lu; Andrew E. Riley; AnnaMartina Tyreus Hufnal; Christopher T. Holding; Corrine L. Lusic; Craig E. Countryman; Daryl L. Wiesen; David M. Fry; Douglas Edward McCann; Elaine H. Blais; Elizabeth M. Flanagan; Ira J. Levy; J. Anthony Downs; Jennifer L. Ford; Jeremy Douglas Anderson; John W. Shaw; Karen Elizabeth Keller; Lana S. Shiferman; Limin NMI Zheng; Michael A. Amon; Nathan Roger Hoeschen; Phillip W. Goter; Robert Frederickson , III.; Robert M. Yeh; Santosh Victor Coutinho; Stephanie E. O'Byrne; Timothy J. Doyle; William Chad Shear; William R. Woodford | ||
| Firms | Fish & Richardson P.C.; Shaw Keller LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA Inc.
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Biologic Drugs cited in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA Inc.
The biologic drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for GlaxoSmithKline LLC v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2014-07-03 | 1 | January 8, 2008, United States Patent No. RE40,000 (“the ’000 patent”), entitled “Method of Treatment…action for infringement of United States Patent No. RE40,000 relating to the use of carvedilol in decreasing…manufacture drug products covered by United States Patent No. RE40,000 for sale and use throughout the United States…original ’069 patent, the ’000 patent expires on June 7, 2015. The ’000 patent is the only patent currently…the ’069 patent. Until it was replaced by the reissued ’000 patent, the ’069 patent had a patent term until | External link to document | |
| 2016-03-02 | 125 | Memorandum and Order | to before the asserted patent, U.S. Patent No. RE40,000 E (the “'000 patent”), issued in January 2008…acts of inducement occurred before there existed a patent to be infringed.”’ (D.I. 115 at 1-2 (quoting Nal…Teva’s validity challenge against the '000 patent)); see also Fed. R. Civ. P. 26(b)(1). 2 The…analyses regarding Teva’s manufacturing decisions and patent enforcement relating to carvedilol), it seems even…2014 25 April 2018 1:14-cv-00878 830 Patent Plaintiff District Court, D. Delaware | External link to document |
| 2016-07-20 | 191 | Report and Recommendations | #x27;069 patent reissued as United States Patent No. RE40,000 (the '"000 patent"), entitled….S. Patent No. 5,760,069 (the '"069 patent"). (Id. at ,-r 35) The '069 patent is entitled…x27;000 patent covered the post-MILVD indication, (SAC at if 40). Patent owners list patents along with…must identify specific patent information with respect to which a claim of patent infringement could &…use or related indication and related patent claim of the patent being submitted" and (2) provide | External link to document |
| 2016-09-19 | 201 | Notice of Service | ., M.P.H. Regarding Infringement of U.S. Patent No. RE40,000 by Teva Pharmaceuticals USA, Inc.; (3) Expert…2014 25 April 2018 1:14-cv-00878 830 Patent Plaintiff District Court, D. Delaware | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
